Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.32M$1.32Mderived−1.3% vs Q4 2022 Net Income-$10.68M-$10.68MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$252,645−5.8% Operating Incomederived-$10,768,189N/M Operating Cash Flowderived-$3,894,792N/M Free Cash Flowderived-$7,610,442N/M Margins · derivedGross margin19.1%−0.9 pt vs Q4 2022
Operating margin-813.3%−390.9 pt vs Q4 2022
Net margin-806.7%−402.8 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end